EU nod for Novartis' triple combo pill builds on hypertension franchise
This article was originally published in Scrip
Executive Summary
The European Commission has approved Novartis' Rasitrio, a triple combination pill containing the company's direct renin inhibitor aliskiren (Rasilez), amlodipine (a widely used calcium channel blocker) and hydrochlorothiazide (HCTZ; a diuretic) for the treatment of high blood pressure.